Publication:
96 weeks of pegylated-interferon- alpha-2α plus tenofovir or placebo for the treatment of hepatitis delta: The hidit-2 study

dc.contributor.authorWedemeyer, Heiner
dc.contributor.authorYurdaydin, Cihan
dc.contributor.authorErnst, Stefanie
dc.contributor.authorCaruntu, Florin A.
dc.contributor.authorCurescu, Manuela G.
dc.contributor.authorYalcin, Kendal
dc.contributor.authorAkarca, Ulus S.
dc.contributor.authorZeuzem, Stefan
dc.contributor.authorErhardt, Andreas
dc.contributor.authorLueth, Stefan
dc.contributor.authorPapatheodoridis, George
dc.contributor.authorKeskin, Onur
dc.contributor.authorPort, Kerstin
dc.contributor.authorCelen, Mustafa K.
dc.contributor.authorStift, Judith
dc.contributor.authorHeidrich, Benjamin
dc.contributor.authorMederacke, Ingmar
dc.contributor.authorHardtke, Svenja
dc.contributor.authorKoch, Armin
dc.contributor.authorDienes, Hans P.
dc.contributor.authorManns, Michael P.
dc.contributor.buuauthorGürel, Selim
dc.contributor.buuauthorGÜREL, SELİM
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi
dc.contributor.researcheridHLH-8209-2023
dc.date.accessioned2024-08-16T08:36:53Z
dc.date.available2024-08-16T08:36:53Z
dc.date.issued2013-10-01
dc.descriptionBu çalışma, 01-05 Kasım2013 tarihleri arasında Washington [ABD]’da düzenlenen 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases’da bildiri olarak sunulmuştur.
dc.description.sponsorshipAmer Assoc Study Liver Dis
dc.identifier.endpage223A
dc.identifier.issn0270-9139
dc.identifier.issueSupplement1, Special IssueSI
dc.identifier.startpage222A
dc.identifier.urihttps://hdl.handle.net/11452/44125
dc.identifier.volume58
dc.identifier.wos000330252201031
dc.indexed.wosWOS.SCI
dc.indexed.wosWOS.ISTP
dc.language.isoen
dc.publisherWiley-blackwell
dc.relation.journalHepatology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectGastroenterology & hepatology
dc.title96 weeks of pegylated-interferon- alpha-2α plus tenofovir or placebo for the treatment of hepatitis delta: The hidit-2 study
dc.typeMeeting Abstract
dspace.entity.typePublication
relation.isAuthorOfPublicationd7a9ea11-69fc-4122-a365-8fb2123512e6
relation.isAuthorOfPublication.latestForDiscoveryd7a9ea11-69fc-4122-a365-8fb2123512e6

Files

Collections